Actively Recruiting
Immune-mediated Pathogenic Mechanisms of Neuro-PASC in Veterans
Led by VA Office of Research and Development · Updated on 2026-03-31
200
Participants Needed
2
Research Sites
162 weeks
Total Duration
On this page
Sponsors
V
VA Office of Research and Development
Lead Sponsor
J
James H. Quillen Department of Veterans Affairs Medical Center
Collaborating Sponsor
AI-Summary
What this Trial Is About
Mental health symptoms, including cognitive impairment ("brain fog"), following COVID-19 are of great concern to Veterans. This research seeks to advance understanding of the long-term effects of COVID-19 on neuropsychiatric and neurological functions, identifying clinically relevant biomarkers and directions for developing and testing therapeutic interventions. To accomplish these objectives the investigators are conducting a longitudinal study at two VA medical centers to: 1) assess and monitor cognitive function and psychiatric symptoms in Veterans post-COVID; 2) evaluate biomarkers of inflammation and signaling pathways associated with viral infection and neuropsychiatric function; and 3) integrate neuropsychiatric and neurological findings with biological data to identify biomarkers and clinical endpoints associated with disease progression or severity, as well as those for promoting brain repair and attenuating those symptoms.
CONDITIONS
Official Title
Immune-mediated Pathogenic Mechanisms of Neuro-PASC in Veterans
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Have a history of SARS-CoV-2 infection at least 4 weeks before enrollment, confirmed by positive PCR or home antigen test
- Able to give informed consent based on a brief cognitive exam and understanding of study risks and benefits
- For neuro-PASC group: currently experience new neuro-PASC symptoms not present before infection, confirmed by the Long COVID-19 Symptom Assessment scale
You will not qualify if you...
- Diagnosed with dementia, traumatic brain injury, Parkinson disease, Alzheimer disease, or other progressive cognitive disorder before SARS-CoV-2 infection
- Diagnosed with a mood or psychotic disorder before SARS-CoV-2 infection
- History of fibromyalgia or chronic fatigue syndrome before SARS-CoV-2 infection
- Have unstable medical conditions or active uncontrolled autoimmune or inflammatory conditions
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 2 locations
1
VA Portland Health Care System, Portland, OR
Portland, Oregon, United States, 97207-2964
Actively Recruiting
2
James H. Quillen VA Medical Center, Mountain Home, TN
Mountain Home, Tennessee, United States, 37684
Not Yet Recruiting
Research Team
J
Jennifer M Loftis, MA PhD
CONTACT
E
Emily R Sano, MA
CONTACT
How is the study designed?
Study Type
OBSERVATIONAL
Masking
N/A
Allocation
N/A
Model
N/A
Primary Purpose
N/A
Number of Arms
2
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here